Physician profile
Mark Ayad Matta
NPI 1245424084
$847,363.65
in general payments reported to CMS, 2019-2025
40 companies · $258K in 2025
The $258K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $26K · 2021: $50K · 2022: $134K · 2023: $141K · 2024: $185K · 2025: $258K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $431K · Travel and Lodging: $102K · Food and Beverage: $25K · Consulting Fee: $25K · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $431,448.63 |
| Travel and Lodging | $101,943.78 |
| Food and Beverage | $24,984.21 |
| Consulting Fee | $24,888.00 |
| Education | $291.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $210,914.98 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206,969.65 | 2020-2025 | Caplyta |
| Alkermes, INC. | $107,533.61 | 2020-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $99,304.30 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $98,898.27 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $46,105.76 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $36,577.41 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $14,613.87 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $7,394.74 | 2019-2022 | |
| Allergan, INC. | $4,985.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,959.30 | 2019-2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,010.29 | 2019-2025 | |
| Almatica Pharma LLC | $1,865.71 | 2022-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $1,209.38 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $1,089.93 | 2019-2025 | Rexulti |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $728.85 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $474.17 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $445.78 | 2021-2025 | Qelbree, Qelbree |
| Acadia Pharmaceuticals INC | $425.75 | 2019-2024 | Nuplazid |
| Corium, LLC | $383.43 | 2022-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $320.97 | 2019-2022 | |
| Indivior INC. | $185.69 | 2019-2023 | Perseris |
| Merck Sharp & Dohme LLC | $124.86 | 2019-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $112.18 | 2023-2024 | Jornay Pm |
| Eisai INC. | $91.56 | 2021-2022 | |
| Sage Therapeutics, LLC | $84.01 | 2024-2025 | Zurzuvae |
| Noven Therapeutics, LLC | $78.15 | 2022-2024 | Xelstrym, Secuado |
| Tris Pharma INC | $76.03 | 2024 | Dyanavel Xr |
| Shire North American Group INC | $64.90 | 2019 | |
| Collegium Pharmaceutical, INC. | $55.41 | 2025 | Jornay Pm |
| Tempus Ai, INC | $49.85 | 2024 | |
| Avion Pharmaceuticals | $45.87 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, Lp | $35.59 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $31.58 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $28.12 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $23.30 | 2019 | |
| Adlon Therapeutics L.P. | $22.73 | 2021 | |
| Bioxcel Therapeutics, INC. | $17.52 | 2023 | Igalmi |
| Noven Pharmaceuticals, INC. | $13.45 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Matta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.